Welcome to DMI BioSciences, Inc. 

DMI BioSciences, Inc. (DMI) is a privately-held clinical stage pharmaceutical company with a global strategy to discover and develop new therapeutic options to treat disease.  Our most advanced drugs address significant unmet needs in men's health, ophthalmology and oncology with three drugs in mid- to late-stage clinical development.  With an expertise that is focused on inflammation and the human plasma proteome, we believe our experience gives us a distinct competitive advantage in discovering new drugs and new uses for approved drugs.

We have full wet lab and mass spectroscopy research capabilities, have successfully discovered and advanced a balanced portfolio of lead candidates in important drug categories and have completed Phase II clinical trials in Europe with our most advanced drug.  Our discovery technologies are equally applicable to orally available small molecules and synthetically manufactured biological drugs.  Our management team has senior level international experience in pharmaceutical and biotech industries and we have a wholly-owned subsidiary in the United Kingdom, DMI BioSciences (U.K.), Ltd., through which we have conducted a substantial amount of our drug development.

We actively seek licensing, partnership and other collaboration opportunities for our early, mid and late-stage product development programs.